Loading organizations...
§ Private Profile · Sydney, New South Wales, Australia
Biotechnology company developing and commercializing colorectal cancer diagnostic products, including the InSure® FIT™ test.
Clinical Genomics Technologies is a Bridgewater, New Jersey-based biotechnology company that develops and commercializes non-invasive diagnostic and monitoring products for colorectal cancer. The privately held firm provides screening assays to healthcare providers and patients, operating primarily through its subsidiary Enterix Inc. to distribute the InSure FIT fecal immunochemical test. The organization is also advancing a specialized two-gene blood assay designed specifically for cancer recurrence monitoring and currently holds a global portfolio of more than 20 patents. To support the ongoing commercialization of its clinical solutions, the enterprise expanded its executive leadership team by appointing industry veterans Laurie Huard as Chief Operating Officer and Karol Ford as Vice President of Sales and Marketing. Clinical Genomics Technologies was founded in 2013 by President and Chief Executive Officer Lawrence LaPointe alongside the original leadership team from Enterix.
Clinical Genomics Technologies has raised $41.0M across 2 funding rounds.
Clinical Genomics Technologies has raised $41.0M in total across 2 funding rounds.
Clinical Genomics Technologies has raised $41.0M across 2 funding rounds. Most recently, it raised $26.0M Other Equity in June 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2018 | $26M Venture Round | — | MA Financial, Paul Kelly, Kristie Dolan, Regal | Announced |
| Mar 23, 2016 | $15M Series A | Paul Kelly | — | Announced |
Clinical Genomics Technologies has raised $41.0M in total across 2 funding rounds.
Clinical Genomics Technologies's investors include MA Financial, Paul Kelly, Kristie Dolan, Regal.